Human Papillomavirus Types 16 and 18 Vaccine (Recombinant, AS04 Adjuvanted, Adsorbed) [Cervarix™]

Cervarix is a prophylactic vaccine comprised of a mixture of virus-like particles derived from the L1 capsid proteins of human papillomavirus (HPV) types 16 and 18 formulated with the AS04 adjuvant system. It is administered by intramuscular injection as a three-dose vaccine regimen at 0, 1 and 6 months. The vaccine is indicated for the prevention of high-grade cervical intraepithelial neoplasia (CIN 2 and CIN 3) and cervical cancer causally related to HPV types 16 and 18. In randomized, double-blind, phase II or III trials in >19,000 women aged 15-25 years, the HPV 16/18 vaccine showed high efficacy in preventing CIN 2+ associated with HPV 16/18. Cross-protection against new incident or 6-month persistent HPV 45 or HPV 31 infection was also evident. Phase II follow-up was for at least 5.5 years, and the phase III interim analysis was at approximately 15 months after the first vaccine dose. In a bridging study, in adolescent girls aged 10-14 years, the HPV 16/18 vaccine induced twice the already high antibody titres as it did in young women (aged 15-25 years). The immune response in older women (aged 26-55 years) at 24 months in another study was >or= 8-fold higher than antibody levels reported in younger age groups. Anti-HPV 16/18 antibody responses were greater with an AS04-adjuvanted HPV 16/18 vaccine than with an aluminium salt-adjuvanted formulation. The HPV 16/18 vaccine was generally well tolerated and injection-site reactions were the most common vaccine-related adverse events reported.

[1]  M. Plummer,et al.  Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis , 2003, British Journal of Cancer.

[2]  S. Franceschi,et al.  Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis , 2003, British Journal of Cancer.

[3]  Cervical Cancer: Effect of Glandular Cell Type on Prognosis, Treatment, and Survival , 2003, Obstetrics and gynecology.

[4]  A. Kaufmann,et al.  Vaccination strategies for the treatment and prevention of cervical cancer , 2004, Current opinion in oncology.

[5]  Daron G Ferris,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.

[6]  I. Eltoum,et al.  Women with atypical glandular cells: a long-term follow-up study in a high-risk population. , 2004, American journal of clinical pathology.

[7]  I. Eltoum,et al.  Women With Atypical Glandular Cells , 2004 .

[8]  Xavier Castellsagué,et al.  Against which human papillomavirus types shall we vaccinate and screen? the international perspective , 2004, International journal of cancer.

[9]  S. Franceschi,et al.  Human Papillomavirus Genotype Distribution in Low-Grade Cervical Lesions: Comparison by Geographic Region and with Cervical Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.

[10]  Ian H. Frazer,et al.  Screening to prevent cervical cancer: Guidelines for the management of asymptomatic women with screen detected abnormalities , 2005 .

[11]  K. Straif,et al.  Carcinogenicity of human papillomaviruses. , 2005, The Lancet. Oncology.

[12]  D. Harper,et al.  Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. , 2005, Vaccine.

[13]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[14]  S. Franceschi,et al.  Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis , 2005, The Lancet.

[15]  E. Rybicki,et al.  Strategies for the prevention of cervical cancer by human papillomavirus vaccination. , 2005, Best practice & research. Clinical obstetrics & gynaecology.

[16]  An AS04-containing human papillomavirus (HPV) 16/18 vaccine for prevention of cervical cancer is immunogenic and well-tolerated in women 15-55 years old. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  N. Garçon,et al.  Development and evaluation of AS04, a novel and improved adjuvant system containing MPL and aluminum salt , 2006 .

[18]  E. J. Mayeaux,et al.  Advances in Prevention of Cervical Cancer and Other Human Papillomavirus-Related Diseases , 2006, The Pediatric infectious disease journal.

[19]  D. Lowy,et al.  Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. , 2006, Vaccine.

[20]  Brigitte Colau,et al.  Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. , 2006, Vaccine.

[21]  Xavier Castellsagué,et al.  Chapter 1: HPV in the etiology of human cancer. , 2006, Vaccine.

[22]  C. Wheeler,et al.  Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial , 2006, The Lancet.

[23]  F. Bray,et al.  Chapter 2: The burden of HPV-related cancers. , 2006, Vaccine.

[24]  J C Aguilar,et al.  Vaccine adjuvants revisited. , 2007, Vaccine.

[25]  J. T. Cox,et al.  American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors , 2007, CA: a cancer journal for clinicians.

[26]  J. Dillner,et al.  Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[27]  M. Schiffman.  Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing , 2007, Cancer.

[28]  Jose Jeronimo,et al.  Human papillomavirus and cervical cancer , 2007, The Lancet.

[29]  M. Lehtinen,et al.  Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. , 2007, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[30]  Henry C Kitchener,et al.  Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial , 2007, The Lancet.

[31]  M. Stanley.  Prophylactic HPV vaccines , 2006, Journal of Clinical Pathology.

[32]  C. Wheeler,et al.  Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine , 2007 .

[33]  J. Metindir.  Vaccination Against Human Papillomavirus Infection in Cervical Cancer Control , 2007 .

[34]  B. Thiers.  American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors , 2008 .

[35]  G. Nahler.  summary of product characteristics (SPC, SmPC) , 2009 .

[36]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[37]  S. Keam,et al.  Human Papillomavirus Types 16 and 18 Vaccine (Recombinant, AS04 Adjuvanted Adsorbed) [Cervarix™] , 2008, Drugs.